Nano-X赢得FDA认可升级心脏成像解决方案

2024-08-21 20:50

Nano-X Imaging (NASDAQ:NNOX) shares traded higher premarket Wednesday after the company announced that its Nanox.AI subsidiary received the FDA's 510(k) clearance for an updated version of its cardiac imaging solution, HealthCCSng.
Named HealthCCSng V2.0, the upgraded product adds new features to HealthCCSng, which is designed to use CT scans to automatically measure coronary artery calcium (CAC), the biggest risk factor for a cardiovascular event.
Nano-X (NNOX) said that HealthCCSng V2.0's new features, such as Zero CAC Category and Numerical CAC Scoring, are expected to help physicians conduct risk assessments and plan preventative healthcare for their patients.
"We are pleased to receive another regulatory clearance from the FDA for our AI cardiac solution, with new updates that reflect our commitment to providing healthcare professionals with the tools they need," CEO Erez Meltzer remarked.

More on Nano-X Imaging